The cost–effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C

References

• USA. Department of health and human services, National institutes of health, National institute of diabetes and digestive and kidney diseases. What I need to know about hepatitis C (NIH Publication No. 13–4229). 2012. Available from: www.niddk.nih.gov/health-information/health-topics/liver-disease/hepatitis-c/Documents/hepc_508.pdf
   Google Scholar
• Bocco D. Chronic Hepatitis C: Symptoms, Diagnosis, and Treatment. In Healthline.com. 2013. Available from: www.healthline.com/health-slideshow/chronic-hepatitis-c#2
   Google Scholar
• Centers for disease control and protection 2015. Hepatitis C FAQs for the a. Public. Available from: www.cdc.gov/hepatitis/c/cfaq.htm [Last accessed 20 March 2015]
   Google Scholar
• USA. Department of health and human services, Office of population affairs 2012. Hepatitis C the facts. Available from: www.hhs.gov/opa/pdfs/hepatitis-c-fact-sheet.pdf
   Google Scholar
• Spach D. HCV epidemiology in the USA. 2014. Available from: www.hepatitisc.uw.edu/go/screening-diagnosis/epidemiology-us/core-concept/all
   Google Scholar
• Najafzadeh M, Andersson K, Shrank WH, et al. Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. Ann Intern Med 2015;162:407-19
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C. Available from: www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html [Last accessed 17 June 2015]
   Google Scholar
• Ly K, Xing J, Klevens R, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-8
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men – New York City, 2005–2010. MMWR Morb Mortal Wkly Rep. 2011.60(28):945-50. Available from: www.cdc.gov/mmwr/preview/mmwrhtml/mm6028a2.htm
   Google Scholar
• Agency for healthcare research and quality. Treatment for hepatitis C virus infection in adults (AHRQ Publication No. 12(13)-EHC113-EF). 2012. Available from: http://effectivehealthcare.ahrq.gov/ehc/products/286/1298/CER76_HepatitisC-Treatment_FinalReport_20121022.pdf
   Google Scholar
• Healthline. Hepatitis C medications: costs, side effects, and more. 2014. Available from: www.healthline.com/health/hepatitis-c-medications-costs-side-effects-and-more#Overview1
   Google Scholar
• Optum. New hepatitis C drugs shake-up the market. 2014. Availabe from www.optum.com/thought-leadership/new-hepatitis-c-drug.html
   Google Scholar
• Franciscus A, Highleyman L. HCV viral load tests. 2014. Available from: www.hcvadvocate.org/hepatitis/factsheets_pdf/viralload.pdf
   Google Scholar
• Linas BP, Barter DM, Morgan JR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162(9):619-U220
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with Sofosbuvir and Ledipasvir in the United States. Ann Intern Med 2015;162:397-U114
   PubMed Web of Science ®Google Scholar
• Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of Sofosbuvir/Ribavirin versus Sofosbuvir/Simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014;60:37-45
   PubMed Web of Science ®Google Scholar
• Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Saab S, et al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544-63
   PubMed Web of Science ®Google Scholar
• Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015;61(2):157-68
   PubMed Web of Science ®Google Scholar
• Linas BP, Morgan JR, Pho MT, et al. The cost-effectiveness of sofosbuvir- and simprevir- based therapies for HCV genotype 1 infection [Abstract P0798]. J Hepatol 2015;62:S633
   Google Scholar
• Forbes. CVS might have tougher times ahead as competition in the PBM market heats up. 2015. Available from: www.forbes.com/sites/greatspeculations/2015/03/02/cvs-might-have-tougher-times-ahead-as-competition-in-the-pbm-market-heats-up/2/
   Google Scholar
• Whalen J. Patients blame cost for coverage delay in england of gilead drug. 2015. Available from: http://blogs.wsj.com/pharmalot/2015/01/22/coverage-for-gileads-sovaldi-is-delayed-in-england-over-cost/
   Google Scholar
• Boseley S. Hepatitis C drug delayed by NHS due to high cost. The Guardian. 2015. Available from: www.theguardian.com/society/2015/jan/16/sofosbuvir-hepatitis-c-drug-nhs
   Google Scholar
• American association for the study of liver diseases & infectious diseases society of America. Recommendations for testing, managing, and treating hepatitis C. 2014. Available from: www.hcvguidelines.org/fullreport
   Google Scholar
• Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state medicaid programs. Ann Intern Med 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Andrews M. Insurers may cover costly hepatitis C drugs only for the Very Ill. 2014. Available from: www.npr.org/sections/health-shots/2014/10/28/359553282/insurers-may-cover-costly-hepatitis-c-drugs-only-for-the-very-ill
   Google Scholar
• Zahnd C, Salazar-Vizcaya L, Wandeler G, et al. Impact of deferring HCV treatment on liver-related events in HIV+ Patients [Abstract 150]. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 2015
   Google Scholar
• Joszt L. Healthcare picks sides in hepatitis C drug battle. 2015. Available from: www.ajmc.com/newsroom/Healthcare-Picks-Sides-in-Hepatitis-C-Drug-Battle
   Google Scholar
• Loftus P. States work to strike deals for hep c drug discounts. 2015. Available from: www.wsj.com/articles/states-work-to-strike-deals-for-hep-c-drug-discounts-1422492687
   Google Scholar
• Ampuero J, Romero-Gómez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther 2014;39(7):686-98
   PubMed Web of Science ®Google Scholar
• Merk. Merck Submits US. New drug application for grazoprevir/elbasvir, an Investigational once-daily, Single tablet combination therapy, for Treatment of chronic hepatitis C genotypes 1, 4, and 6 infection. 2015. Available from: www.mercknewsroom.com/news-release/hepatitis-c-newsroom/merck-submits-us-new-drug-application-grazoprevirelbasvir-investig
   Google Scholar
• Gilead. gilead announces phase 2 data for investigational all-oral regimen of sofosbuvir plus GS-5816 for the treatment of chronic hepatitis C. 2014. Availble from www.gilead.com/news/press-releases/2014/11/gilead-announces-phase-2-data-for-investigational-alloral-regimen-of-sofosbuvir-plus-gs5816-for-the-treatment-of-chronic-hepatitis-c
   Google Scholar
• Gilead. Gilead announces data for investigational, All-Oral, Pan-genotypic three-drug regimen of sofosbuvir, GS-5816 and GS-9857 for chronic hepatitis C. 2015. Available from: www.gilead.com/news/press-releases/2015/4/gilead-announces-data-for-investigational-alloral-pangenotypic-threedrug-regimen-of-sofosbuvir-gs5816-and-gs9857-for-chronic-hepatitis-c
   Google Scholar
• Gilead. Pipeline. 2009-2013. Available from: www.gilead.com/research/pipeline
   Google Scholar
• Bristol-Myers Squibb. Bristol-myers squibb receives US. FDA breakthrough therapy designation for all-oral daclatasvir dual investigational regimen for chronic hepatitis C. 2014. Available from: http://news.bms.com/press-release/bristol-myers-squibb-receives-us-fda-breakthrough-therapy-designation-all-oral-daclata
   Google Scholar